Abstract
Dr. Tomisaku Kawasaki was the first to describe BCG reactivation in Kawasaki Disease (KD), and this sign is present in about 30–50% of KD patients. It is a very specific early sign of the disease and although it has been recognized for decades, its pathophysiology continues to be an enigma. Recently, Yamada et al. reported a severe BCG reaction with tuberculid in 2 Japanese KD patients. We present 2 cases with KD and severe BCG reaction, one from Japan and the other from Mexico and review the policies of administration of BCG in both countries. The BCG vaccine has a worldwide coverage of 88%. Differences in BCG strains and methods of administration may influence BCG reactions in KD. The BCG reaction in the inoculation site may represent the most useful sign in KD.
Author supplied keywords
Cite
CITATION STYLE
Gamez-Gonzalez, L. B., Hamada, H., Llamas-Guillen, B. A., Ruiz-Fernandez, M., & Yamazaki-Nakashimada, M. (2017, May 4). BCG and Kawasaki disease in Mexico and Japan. Human Vaccines and Immunotherapeutics. Taylor and Francis Inc. https://doi.org/10.1080/21645515.2016.1267083
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.